Oct 31, 2024 / 12:30PM GMT
Editor
Portions of this transcript marked (technical difficulty) indicate audio problems. The missing text will be supplied if a replay becomes available.
Nello Mainolfi - Kymera Therapeutics Inc - President, Chief Executive Officer, Co-Founder, Director
(technical difficulty) In addition, given that th two diseases are highly prevalent in Children, we believe this has the potential to be a drug that will change the quality of life for many families in the future.
Our next update is expected to be upon completion of the healthy volunteer study in the first half of 2025. At which point, we will share the full results following the completion of the phase one study. Our plan is to move quickly into patients. We have those plans well established and we expect to provide guidance on the next stage of 6 to 1 clinical development. Next year, Jared will share more details around the ongoing phase one study later in the call.
I also wanted to briefly highlight another important update on KT-474. Our first in class IREC four degrader. This is another program
Q3 2024 Kymera Therapeutics Inc Earnings Call Transcript
Oct 31, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers